Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Chronic hepatitis C, Genotype 2 or 3~* Naïve to prior anti-HCV therapy~Exclusion Criteria:~* Infected with HCV other than Genotype 2 or 3~* Positive Hepatitis B surface antigen (HBsAg), or Human immunodeficiency virus-1 (HIV-1)/HIV-2 antibody at screening~* Evidence of liver disease other than HCV~* Active substance abuse~* Evidence of decompensated cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: pegIFNλ + Ribavirin + Placebo matching Daclatasvir (Type: EXPERIMENTAL): None
- Arm 2: pegIFNλ + Ribavirin + Daclatasvir (Type: EXPERIMENTAL): None
- Arm 3: pegIFNα-2a + Ribavirin + Placebo matching Daclatasvir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).